We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
RIFADIN rifampicin 300 mg capsules (UK)
Section 19A approved medicine
RIFADIN rifampicin 300 mg capsules (UK)
Section 19A approval holder
Link Medical Products Pty Ltd ABN 73 010 971 517
Phone
1800 181 060
Approved until
Status
Current
Medicines in short supply/unavailable
RIFADIN rifampicin 300mg capsules blister pack - ARTG 233443
Indication(s)
Tuberculosis
- In the initial treatment and in re-treatment of patients with tuberculosis, Rifadin must be used in conjunction with at least one other antituberculosis drug.
Leprosy
- In the management of lepromatous leprosy and dimorphous leprosy to effect speedy conversion of the infectious state to the noninfectious state, which may be expected to occur in 3 to 4 months of treatment.
- As an alternative drug in lepromatous, dimorphous, indeterminate and tuberculoid leprosy resistant to sulfones and other antileprosy drugs.
- As an alternative drug in all those patients having true drug allergy to the more commonly used antileprosy drugs.
Meningococcal Disease
- Prophylaxis of meningococcal disease in close contacts of known cases and in carriers (Rifadin is not indicated for the treatment of meningococcal infections).
Haemophilus Influenzae
- Prophylaxis of household contacts of patients with H. influenzae type B.
Images
